


**Listing of Claims:**


Claims 2-13 (cancelled)

**Claim 14 (new)** A compound of general formula (I')



wherein

A is



R<sub>18</sub>, R<sub>19</sub> and R<sub>20</sub> are independently selected from the group consisting of hydrogen, halogen, -OH, SR<sub>23</sub>, alkyl or alkoxy of 1 to 6 carbon atoms, alkenyl of up to 6 carbon atoms and -NR<sub>24</sub>R<sub>25</sub>, R<sub>21</sub> and R<sub>22</sub> are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or R<sub>21</sub> and R<sub>22</sub> form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently selected from the group consisting of O, N and S, or furthermore R<sub>21</sub> is

selected from the group consisting of alkylsulfonyl, alkylsulfoxide and alkylcarbonyl and then R<sub>22</sub> is hydrogen, R<sub>23</sub> is hydrogen or alkyl of 1 to 6 carbon atoms, R<sub>24</sub> and R<sub>25</sub> are independently selected from the group consisting of hydrogen, OH, alkyl of 1 to 6 carbon atoms and -CO-R<sub>26</sub>, R<sub>26</sub> is alkyl of 1 to 6 carbon atoms,

B is selected from the group consisting of alkyl of 1 to 6 carbon atoms, -NR<sub>34</sub>R<sub>35</sub>, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms selected from the group consisting of O, S and N, the aryl radical being optionally substituted by at least one member selected from the group consisting of alkyl or alkoxy of 1 to 6 carbon atoms and alkenyl of up to 6 carbon atoms,

R<sub>34</sub> and R<sub>35</sub> are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or R<sub>34</sub> and R<sub>35</sub> form together with the nitrogen atom a non-aromatic heterocycle with five to six members, each of the elements of the chain being selected from the group consisting of -CH<sub>2</sub>-, -NH-, -O- and -S-,

X is selected from the group consisting of a bond, -(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-CO-, -O-(CH<sub>2</sub>)<sub>m</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>-, -NR<sub>36</sub>-(CH<sub>2</sub>)<sub>m</sub>-, -CO-NR<sub>36</sub>-, -O-(CH<sub>2</sub>)<sub>m</sub>-CO-, -S-(CH<sub>2</sub>)<sub>m</sub>-CO-, -NR<sub>36</sub>-(CH<sub>2</sub>)<sub>m</sub>-CO-, -(CH<sub>2</sub>)<sub>m</sub>-C(OH)(CH<sub>3</sub>)-CO-, -CH=CH and -CH=N-,

Y is selected from the group consisting of a bond, -(CH<sub>2</sub>)<sub>n</sub>- and -(CH<sub>2</sub>)<sub>r</sub>-Q-(CH<sub>2</sub>)<sub>s</sub>-,

Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine, thiazolidine and a saturated carbon ring having 3 to 7 members,

Φ is selected from the group consisting of a bond,  $-(CH_2)_p-O-(CH_2)_q-$ ,  $-(CH_2)_p-S-(CH_2)_q-$ ,  $-(CH_2)_p-NR_{37}-(CH_2)_q-$ ,  $-(CH_2)_p-CO-NR_{37}-(CH_2)_q-$ , and  $-CO(CH_2)_p-NR_{37}-(CH_2)_q-$ ,

$R_{36}$  and  $R_{37}$  are independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and  $-CO-R_{38}$ ,  $R_{38}$  is alkyl or alkoxy of 1 to 6 carbon atoms,

$R_{39}$  is selected from the group consisting of hydrogen and alkyl or alkoxy of 1 to 6 carbon atoms,

$m$ ,  $n$ ,  $p$ ,  $q$ ,  $r$  and  $s$  are independently integers from 0 to 6,

and its pharmaceutically acceptable salts.

**Claim 15 (new)** A compound of claim 14 wherein  $R_{18}$ ,  $R_{19}$  and  $R_{20}$  are independently selected from the group consisting of hydrogen, OH and alkyl or alkoxy of 1 to 6 carbon atoms,  $R_{21}$  and  $R_{22}$  are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or  $R_{21}$  and  $R_{22}$  form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being

independently selected from the group consisting of O, N and S, or R<sub>21</sub> is alkylsulfonyl or alkylcarbonyl and R<sub>22</sub> is hydrogen,

B is selected from the group consisting of alkyl of 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms selected from O, S and N, the aryl radical being optionally substituted by at least one member selected from the group consisting of alkyl or alkoxy of 1 to 6 carbon atoms and alkenyl of up to 6 carbon atoms,

X is selected from the group consisting of a bond or -(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-CO, -O-(CH<sub>2</sub>)<sub>m</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>-, -NR<sub>36</sub>-(CH<sub>2</sub>)<sub>m</sub>-, -CO-NR<sub>36</sub>-, -O-(CH<sub>2</sub>)<sub>m</sub>-CO-, -S-(CH<sub>2</sub>)<sub>m</sub>-CO-, -NR<sub>36</sub>-(CH<sub>2</sub>)<sub>m</sub>-CO- and -(CH<sub>2</sub>)<sub>m</sub>-C(OH)(CH<sub>3</sub>)-CO-,

Y is selected from the group consisting of a bond, -(CH<sub>2</sub>)<sub>n</sub>- and -(CH<sub>2</sub>)<sub>r</sub>-Q-(CH<sub>2</sub>)<sub>s</sub>-,

Q is selected from the group consisting of piperazine, piperidine, 1,2,3,6-tetrahydropyridine, azetidine, thiazolidine and a saturated carbon ring having 3 to 7 members,

Φ is a bond or -(CH<sub>2</sub>)<sub>p</sub>-O-(CH<sub>2</sub>)<sub>q</sub>-,

R<sub>36</sub> and R<sub>37</sub> are independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and -CO-R<sub>38</sub> in which R<sub>38</sub> is alkyl or alkoxy of 1 to 6 carbon atoms;

$R_{39}$  is selected from the group consisting of hydrogen and alkyl and alkoxy of 1 to 6 carbon atoms,

$m$ ,  $n$ ,  $p$ ,  $q$ ,  $r$  and  $s$  are independently integers from 0 to 6;

and a salt thereof.

**Claim 16 (new)** A compound of claim 14, wherein B is selected from the group consisting of thiophene, furan, pyrrole and thiazole.

**Claim 17 (new)** A compound of claim 16 wherein B is thiophene.

**Claim 18 (new)** A compound of claim 14 wherein  $R_{21}$  is alkyl of 1 to 6 carbon atoms and  $R_{22}$  is alkyl of 1 to 6 carbon atoms.

**Claim 19 (new)** A compound of claim 14 wherein  $R_{39}$  is hydrogen.

**Claim 20 (new)** A compound of claim 14 selected from the group consisting of

- 2-amino-N-(4-{{[amino(2-thienyl)methylidene]amino}phenethyl)-5-methoxybenzamide;
- 5-amino-N-(4-{{[amino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxybenzamide;
- 4-(4-{{[amino(2-thienyl)methylidene]amino}phenyl)-N-{{4-[(methylsulphonyl)amino]phenyl}butanamide;
- 4-(4-{{[amino(2-thienyl)methylidene]amino}phenyl)-N-[4-(dimethylamino)phenyl]butanamide;
- 5-(4-{{[amino(2-thienyl)methylidene]amino}phenyl)-N-[4-(dimethylamino)phenyl]pentanamide;
- (4*R*)-2-(3-{{[amino(2-thienyl)methylidene]amino}-phenyl)-N-[4-(dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide;
- *tert*-butyl 3-{{[amino(2-thienyl)methylidene]amino}benzyl}{3-[4-(dimethylamino)anilino]-3-oxopropyl}carbamate;
- 3-[(3-{{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]propanamide;
- 3-[(3-{{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-morpholinyl)phenyl]propanamide;
- N'-[4-(2-{{[5-(dimethylamino)-2-hydroxybenzyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;
- N-(4-{{(4-{{[amino(2-thienyl)methylidene]amino}phenethyl)-amino}methyl}phenyl)acetamide;
- N'-[4-(2-{{[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;
- N'-{4-[2-{{[4-(dimethylamino)anilino]carbonyl}amino}-ethyl]phenyl}-2-thiophenecarboximidamide;
- N'-{4-[2-{{[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methyl)amino}ethyl}phenyl]-2-thiophenecarboximidamide;

and the pharmaceutically acceptable salts of the latter.

**Claim 21 (new)** A method of inhibiting NO synthase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 22 (new)** A method of inhibiting lipidic peroxidation in a patient in need thereof comprising administrating to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 23 (new)** A method of inhibiting both NO synthase and lipidic peroxidation in a patient in need thereof comprising administrating to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 24 (new)** A method of treating a neurodegenerative disease in a patient in need thereof comprising administrating to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 25 (new)** The method of claim 24 wherein the neuorodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld Jacob disease and amyotrophic lateral sclerosis.